reports
FormFactor Introduces Flatiron™ Dilution Refrigerator for Benchtop Mil...
FormFactor Introduces Flatiron™ Dilution Refrigerator for Benchtop Millikelvin Research and Quantum Hardware Validation Flatiron™ Platform Simplifies Sub‑Kelvin Optical and Electrical Measurements and Accelerates Time‑to‑Data for Research and Industry LIVERMORE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a leading semiconductor test and measurement supplier, today introduced the Flatiron™ Dilution Refrigerator, a new benchtop millikelvin platform designed to simplify sub‑kelvin optical and electrical measurements and accelerate quantum device development...
Antero Resources Corp: 2 directors
Two Directors at Antero Resources Corp sold after exercising options/sold 34,667 shares at between 38.130USD and 39.330USD. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Arq Reports Fourth Quarter and Full Year 2025 Results
Arq Reports Fourth Quarter and Full Year 2025 Results Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided inaugural financial guidance for full-year 2026 Pausing GAC production and development to conduct comprehensive engineering and production process optimization review Announced leadership changes, including appointment of industry veteran as VP Operations and Finance team reorganization GREENWOOD VILLAGE, Colo., March...
Emcor Group Inc: 1 director
A director at Emcor Group Inc sold 36,000 shares at 729.480USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Candel Therapeutics To Present New Data after Extended Follow Up from ...
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Ur...
FormFactor to Host Upcoming Investor Day
FormFactor to Host Upcoming Investor Day LIVERMORE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a leading provider of essential test and measurement technologies enabling next-generation semiconductor innovation, today announced that it will host its Investor Day at the Nasdaq MarketSite in New York City. Location: Nasdaq MarketSite at 151 W 43rd Street, 10th Floor Date & Time: May 11th, 2026 from 10:00 am to 1:00 pm Eastern Time During the event, members of FormFactor’s executive leadership team will provide an in‑depth review of FormFactor’s strategic p...
Northrop Grumman Corp: 2 directors
A director at Northrop Grumman Corp sold/sold after exercising options 873 shares at 745.000USD and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
Annovis Announces Two Presentations at the AD/PD™ 2026 International C...
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (), taking place March 17-21, 2026, in Copenhagen, Denmark. The presentations will highlight cl...
CECO Environmental Announces Upcoming Investor Conferences
CECO Environmental Announces Upcoming Investor Conferences ADDISON, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announces that CECO management will participate at the following investor conferences: March 5, 2026 – Citadel SMID Cap Generalist Investor ConferenceMarch 24, 2026 – 38th Annual Roth ConferenceApril 9, 2026 – Gabelli Funds’ 12th Waste & Environmental Services Symposium The presentations will b...
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 20,000 shares of the Company’s common stock, with a per share exercise pric...
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Resul...
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evor...
Churchill Downs Incorporated Reports 2025 Fourth Quarter and Full Year...
Churchill Downs Incorporated Reports 2025 Fourth Quarter and Full Year Results LOUISVILLE, Ky., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company", "CDI", "we") today reported business results for the quarter and full year ended December 31, 2025. Company Highlights Fourth quarter 2025 financial results, as compared to the prior year quarter: Record net revenue $665.9 million, up $41.7 million or 7%Net income attributable to CDI of $51.3 million, down $20.4 million or 28%Record Adjusted EBITDA of $247.0 million, up $10.4 million or 4% On Septemb...
Churchill Downs Incorporated Opens Marshall Yards Racing & Gaming in S...
Churchill Downs Incorporated Opens Marshall Yards Racing & Gaming in Southwestern Kentucky $40-45 Million Investment Provides World-Class Entertainment While Supporting Funding for the Oak Grove Race Meet LOUISVILLE, Ky., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (“CDI” or “the Company”) (Nasdaq: CHDN) announced the grand opening of Marshall Yards Racing & Gaming (“Marshall Yards”) to the public on February 25, 2026, the Company’s eighth premier historical horse racing entertainment venue in Kentucky. The 23,000 square foot venue in Calvert City, Kentucky features 2...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TTMI TTM TECHNOLOGIES INC.
PFG PRINCIPAL FINANCIAL GROUP INC.
LGIH LGI HOMES INC.
GTE GRAN TIERRA ENERGY
GOOD GLADSTONE COMMERCIAL CORPORATION
GLW CORNING INC
FAN FABRINET
FIX COMFORT SYSTEMS USA INC.
CUBE CUBESMART
CIEN CIENA CORPORATION
AXTI AXT INC.
AAOI APPLIED OPTOELECTRONICS INC.
COHU COHU INC.
OXM OXFORD INDUSTRIES INC.
RELL RICHARDSON ELECTRONICS LTD.
AEHR AEHR TEST SYSTEMS
UAA UNDER ARMOUR INC. CLASS A
TNDM TANDEM DIABETES CARE
FNKO FUNKO CLASS A
ST SENSATA TECHNOLOGIES HOLDING PLC
VICR VICOR CORP.
ATOM ATOMERA
MMMB MAMAMANCINI'S HOLDINGS INC
STNE STONECO
MRNA MODERNA INC.
ATEX ANTERIX INC
XP XP
PRDO PERDOCEO EDUCATION CORP
JAKK JAKKS PACIFIC INC.
SHLS SHOALS TECHNOLOGIES GROUP
COHR COHERENT CORP
SYRE SPYRE THERAPEUTICS INC.
LGCY LEGACY EDUCATION INC.
HOII REX HOOD GROWTH & INCOME ETF
MDLN MEDLINE INC
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care C...
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, ...
Arq Schedules Fourth Quarter & Full-Year 2025 Earnings Conference Call
Arq Schedules Fourth Quarter & Full-Year 2025 Earnings Conference Call GREENWOOD VILLAGE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- GlobeNewswire - Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced the Company will release its fourth quarter and full-year 2025 financial results after market close on Monday, March 9, 2026. A conference call to discuss the Company's financial performance is scheduled for Tuesday, March 10, 2026 at 8:30 a.m. Eas...
CECO Environmental Reports Fourth Quarter and Full Year 2025 Results
CECO Environmental Reports Fourth Quarter and Full Year 2025 Results Delivered Multiple Financial Records Including Full Year Orders Greater Than $1 BillionFinished 2025 Strong with Q4 Gross Profit Margins of 35%Announces Strategic Transaction Combining CECO with Thermon GroupRaises 2026 Full Year Outlook – Non-Inclusive of Thermon ADDISON, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) ("CECO"), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.